TrialBritish journal of cancer2015

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.

P A Jänne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.